Navigation Links
Bringing New Cell Therapies to Market Requires Top-Notch Logistics and Operational Efficiency
Date:1/24/2013

Rockville, Maryland (PRWEB) January 24, 2013

(January 22nd, 2013) — Fisher BioServices, the world’s leading provider of biospecimen storage, cell therapy logistics and related clinical trial services, announced today that Mr. Dan O’Donnell, Associate Director of Cell Therapy Logistics at Fisher BioServices, and Mr. Bruce C. Simpson, Director of Commercial Operations at Fisher BioServices, will be presenting at the 2013 Phacilitate Cell & Gene Therapy Forum, January 28-30, in Washington, DC. This year’s Forum focuses on bringing therapeutics “From Promise to Products” and features presentations and roundtable discussions on positioning new cell and gene therapies for commercial success.

Companies with cell-based therapies nearing clinical trials and FDA approval face the challenge of transporting their product in compliance with FDA requirements for cold chain / chain of custody documentation. Mr. O’Donnell and Mr. Simpson are recognized industry experts on the handling and distribution of gene and cell-based therapies, and will be sharing the latest innovations on the distribution of cell-based products and regenerative medicines from the manufacturer to the patient, while complying with all applicable Title 21 CFR criteria.

The critical issues of commercial viability will be addressed in the first plenary session, and will include valuing cell therapies, reimbursement in the current healthcare environment, and other factors that may influence a product’s commercial success, including distribution systems.

During this session, Mr. O’Donnell will outline the variables that must be considered during every point of transfer in the delivery of cell therapies to the patient, and will discuss the challenges and technical considerations involved in moving cryogenically frozen products around the world.
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ORNL wins 9 R&D 100s, bringing total to 173
2. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
6. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
7. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
8. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
9. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
10. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
11. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... According to a new market research ... & Non-Portable), Component (Accelerometer, Proximity Probe, & Others), ... Mining, & Others), & Geography - Global Forecast ... reach $1,453.76 Million by 2020, at a CAGR ... and 92 figures spread through 205 pages and ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
(Date:4/29/2015)... 29, 2015 Cambrex Corporation (NYSE: CBM ) ... on Friday, May 1, 2015 before the market opens. ... will host a conference call to discuss the financial results. ... , Friday, May 1, 2015 at 8:30 a.m. ... for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma., ... therapy has processed more than 11,000 samples. VetStem ... treatment for horses with potentially fatal injuries to tendons ... exclusive license for adipose-derived (fat derived) stem cell technology ... in January 2004. Shortly after, the first dogs were ...
Breaking Biology Technology:Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... Dec. 21 Ipsogen SA (Alternext: ALIPS) today announced ... tumor grade in chemotherapy prescription has been presented at ... December 9-13, 2009. , The study was conducted ... Using the centre database and a classification tree method, ...
... , - Company,s results amongst the ... CITY, Dec. 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) ... affordable vaccines based on proprietary manufacturing technologies and Virus-Like ... Phase I human clinical trial with its H5N1 Avian ...
... METTLER TOLEDO recently ... FTIR Analytics as a Process Analytical Technology (PAT), on January 20, 2010. , ... (PRWEB) December 20, 2009 -- METTLER TOLEDO ... In Situ FTIR Analytics as a Process Analytical Technology (PAT), on January 20, ...
Cached Biology Technology:Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 3Medicago reports positive Phase I results for its avian flu pandemic vaccine 4Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... animal models is enabling a deeper understanding of the ... that may lead to more effective treatment options to ... The findings were released today at Neuroscience 2009, the ... source of emerging news about brain science and health. ...
... a child,s speech development if the habit goes on ... in Patagonia, Chile, researchers associated the persistence of these ... in preschool children. The children were more likely to ... their pronunciation. The results were published Wednesday, Oct. ...
... the environmental equivalent of the ASX200 as a means of ... of an ecosystem can be understood by measuring the right ... of the Australian stock market by following 200 selected stocks. ... Hayes, one of the leaders of the project, says the ...
Cached Biology News:Studies improve knowledge of underlying brain changes caused by addiction 2Infant sucking habits may affect how baby talks 2Finding the ASX200 for marine ecosystems 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... ES1301 mutS are mismatch repair minus strains ... prevents repair of the newly synthesized unmethylated ... and making them helpful in such systems ... Mutagenesis Systems. Both ES1301 and BMH 71-18 ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: